Emerald Health Therapeutics Stock (TSXV: EMH) (OTC: TBQBF) - Investor Dashboard


➔ Emerald Health Therapeutics
TSX Venture Exchange: EMH
OTC Ticker: TBQBF
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees:  18
Established: 2013
CEO: Dr. Bin Huang

Summary

Fiscal Year-End: December
License Renewal Month: May 2018
Licenses: 1
Licensed Capacity:  150kg / 648kg oil
Number of Patients:  N/A
Headquarters: Victoria, BC

Financials (09/30/16)

Cash on hand: $0.875mm
Fixed Investment: $0.563mm
Shareholders’ Equity: $1.234mm
Revenues – Last Quarter: $49K
Adj. Gross Margin : -283.9%
EPS : -$0.02

Capital Structure (02/10/17)

Last Financing: 10.235mm Units at $1.35
Basic Shares: 77.5mm
Warrants: 13.6mm
Options: 5.9mm
Diluted Shares: 97.0mm

Looking for data that isn’t here or have a question? Let us know.


Company Brief

Emerald Health Therapeutics, formerly T-Bird Pharma, Inc., is based in British Columbia and federally licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Emerald Health was the 8th company to be licensed by Health Canada and began trading publicly in 2015. Emerald Health, which wholly owns Emerald Botanicals, has a clear biotech focus and earned a federal research grant that allows it to investigate cannabis strains and new cultivation technologies. Its access to widely recognized experts in development of botanical, nutraceutical and pharmaceutical medicines and the ability to carry out clinical trials is helping lead the way for the future of medicinal cannabis.

Emerald StructureOver 67% of EMH shares are owned by Emerald Health Sciences, controlled by Dr. Avtar Dhillon. “Dr. Dhillon and his team bring a wealth of experience in the pharmaceutical and nutraceutical sectors, and he is the current chairman of Inovio Pharmaceuticals (NASDAQ: INO, US $500 MM mkt cap.),” according to Dundee Capital in its recent research piece.

Market Comparison

Emerald-Health-Therapeutics-Products


Highlights

  • Leadership team with MDs, PhDs, engineers and horticulturists with extensive experience, collectively offering more than 60 years of cannabis growing leadership, knowledge and commitment
  • Significant insider ownership
  • Major facility expansion project
  • Science-based products

Growth Strategy

  • Increase patients
  • Increase sales
  • Scale up extraction
  • Second site licenses
  • 100,000 sq. ft. grow facility

Differentiators

  • Genetic diversity
  • Pharmaceutical standards
  • Clinical studies
  • Standardized dosage and delivery
  • GMP-compliant extraction and processing

Institutional Analyst Coverage

DANIEL PEARLSTEIN
Eight Capital Markets


Curated Stories & News


Visit Emerald Health
at www.emerald.care.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Emerald Health Therapeutics, Inc., is a client of NCV Media, LLC. Read our full disclaimer.

Latest News
Get The App

Download the free “New Cannabis Ventures” app on the iOS App Store or Google Play and get real-time push notifications straight to your phone on the latest breaking news and exclusives published.


ncv-news-ios-app-store

ncv-news-google-play

NCV Media, LLC

Thank you for reading

New Cannabis Ventures

Contributing original content and curating quality news on only the most promising cannabis companies and the most influential investors.

FOLLOW US ON